



GOLDFINGER
COMMUNICATIONS

Therapix Biosciences' board of directors is joined by Stephen M. Simes

- **Simes has extensive experience in the management of pharma companies in the U.S.**
- **The appointment is designed to strengthen the management team towards the expansion of the Company's activity abroad**

Tel Aviv, Israel. Therapix Biosciences, (OTC: THXBY) (TASE: THXBY.TA) the cannabinoid-based drugs, announced its intention to add Mr. Stephen M. Simes to the Company's board of directors. Simes has extensive experience as a board member and in the management of private and public pharma companies in the U.S., including BioSante Pharmaceuticals, Inc. and Unimed Pharmaceuticals, Inc. and has a strong connection to Israel.

Such appointment joins a host of additional appointments made by Therapix in recent months, including the joining of internationally renowned experts in the fields of psychiatry, neurology and chemistry – with a view to strengthen its team of researchers, consultants and management towards the expansion of the Company's activity abroad.

Dr. Ascher Shmulewitz, Therapix's Chairman, stated that "we believe that Simes's appointment will significantly contribute to the establishment of Therapix's international position and the advancement of its business activity overseas"

About Therapix

Therapix is an Israeli pharma company specializing in the development and commercialization of approved drugs that are based on cannabinoid molecules. The Company is listed on the Tel Aviv Stock Exchange and is also traded over-the counter (OTC) in the United States. The Company is engaged in the development of a drug based on cannabinoids and the entourage technology for treating Tourette syndrome, and is preparing for the development of a cannabinoid-based drug for treating impairments in cognitive functioning (including preliminary stages of Alzheimer's disease).

For further details, Goldfinger Communications, Irit Yosilevitch, 052-3887799

